In this revised Program Project renewal application, the applicant group is representative of three primary institutions. The Ohio State University (OSU), the University of Illinois at Chicago (UIC), and the University of North Carolina at Greensboro (UNCG). The participants have combined their vast experience in the isolation, structure elucidation, and biological evaluation of natural products, to continue the development of a consolidated, integrated program for the discovery of novel anticancer agents of diverse origin for development as cancer chemotherapeutic agents. Plant materials to be studied in Project 1 (OSU) will be collected by established botanists located in tropical countries with the assistance of the NAPRALERT database (Project 2;UIC), and cyanobacteria (Project 2) and filamentous fungi (Project 3 UNCG) will also be accessed. Organisms acquired will be extracted and evaluated in a diverse battery of relevant mechanism-based, cell-based, and tumor-growth related assays currently operational at OSU (Project 1), UIC (Core A), Columbia University (through Project 3), and a new pharmaceutical company partner, Eisai Inc., Andover, MA (through Core C at OSU). Dereplication of known active compounds will be accomplished at OSU, UIC, and UNCG using computerized literature surveys and LC-MS coupled to bioassays. Bioassay-directed fractionation will be employed in Projects 1-3, for the elucidation of active principles. Lead development of active natural products via medicinal chemistry and pharmacokineticsrelated studies will be conducted at OSU (Core B), facilitated by the OSU Biostatistics group (Core C). Novel, active compounds thus discovered will be further evaluated in our panel of in vitro and in vivo bioassays (Projects 1 and 3, Cores A and Eisai). Group decisions will be made regarding the further development of agents for potential use as anticancer agents. The more advanced states of biological and toxicological testing, as well as the procurement of larger quantities of lead compounds will be sponsored by Eisai (through Core C). The Consortium will work with the involvement of the NCI Program Director in the discovery process, and plans to hold regular meetings of key scientific personnel (inclusive of our External and OSU Internal Advisory panels) to enhance communication and decision-making processes, to be organized by Core C. Excellent facilities for the isolation, structure determination, chemical modification, synthesis, and in vitro and in vivo biological evaluation, and overall project data management are available.

Public Health Relevance

Cancer is responsible for about one in every four deaths in the United States, and new treatments are urgently needed. It is the overall goal of the integrated studies in this renewal application to discover novel chemicals from selected tropical rainforest plants, as well as cyanobacteria and fungi, for development as cancer chemotherapeutic agents, particularly for tumors not cured by present treatment methods.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA125066-06A1
Application #
8608726
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (O1))
Program Officer
Fu, Yali
Project Start
2006-12-01
Project End
2019-04-30
Budget Start
2014-06-06
Budget End
2015-04-30
Support Year
6
Fiscal Year
2014
Total Cost
$1,484,104
Indirect Cost
$247,118
Name
Ohio State University
Department
Type
Schools of Pharmacy
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Sica, Vincent P; Rees, Evan R; Raja, Huzefa A et al. (2017) In situ mass spectrometry monitoring of fungal cultures led to the identification of four peptaibols with a rare threonine residue. Phytochemistry 143:45-53
Henkin, Joshua M; Sydara, Kongmany; Xayvue, Mouachanh et al. (2017) Revisiting the linkage between ethnomedical use and development of new medicines: A novel plant collection strategy towards the discovery of anticancer agents. Journal of medicinal plant research 11:621-634
Paguigan, Noemi D; Al-Huniti, Mohammed H; Raja, Huzefa A et al. (2017) Chemoselective fluorination and chemoinformatic analysis of griseofulvin: Natural vs fluorinated fungal metabolites. Bioorg Med Chem 25:5238-5246
Wang, Jiang; Zhu, Xiaohua; Kolli, Shamala et al. (2017) Plasma pharmacokinetics and bioavailability of verticillin A following different routes of administration in mice using liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal 139:187-192
Chen, Wei-Lun; Ren, Yulin; Ren, Jinhong et al. (2017) (+)-Strebloside-Induced Cytotoxicity in Ovarian Cancer Cells Is Mediated through Cardiac Glycoside Signaling Networks. J Nat Prod 80:659-669
Paguigan, Noemi D; El-Elimat, Tamam; Kao, Diana et al. (2017) Enhanced dereplication of fungal cultures via use of mass defect filtering. J Antibiot (Tokyo) 70:553-561
Ren, Yulin; Chen, Wei-Lun; Lantvit, Daniel D et al. (2017) Cardiac Glycoside Constituents of Streblus asper with Potential Antineoplastic Activity. J Nat Prod 80:648-658
Acuña, Ulyana Munoz; Curley Jr, Robert W; Fatima, Nighat et al. (2017) Differential Effect of Wortmannolone Derivatives on MDA-MB-231 Breast Cancer Cells. Anticancer Res 37:1617-1623
Ren, Yulin; Gallucci, Judith C; Kinghorn, A Douglas (2017) An Intramolecular CAr-H•••O=C Hydrogen Bond and the Configuration of Rotenoids. Planta Med 83:1194-1199
Brooks, Wilson C; Paguigan, Noemi D; Raja, Huzefa A et al. (2017) qNMR for profiling the production of fungal secondary metabolites. Magn Reson Chem 55:670-676

Showing the most recent 10 out of 126 publications